Literature DB >> 24874714

Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.

Pierre-Eric Lutz1, Gulebru Ayranci2, Paul Chu-Sin-Chung2, Audrey Matifas2, Pascale Koebel2, Dominique Filliol2, Katia Befort2, Abdel-Mouttalib Ouagazzal2, Brigitte L Kieffer3.   

Abstract

Addiction is a chronic disorder involving recurring intoxication, withdrawal, and craving episodes. Escaping this vicious cycle requires maintenance of abstinence for extended periods of time and is a true challenge for addicted individuals. The emergence of depressive symptoms, including social withdrawal, is considered a main cause for relapse, but underlying mechanisms are poorly understood. Here we establish a mouse model of protracted abstinence to heroin, a major abused opiate, where both emotional and working memory deficits unfold. We show that delta and kappa opioid receptor (DOR and KOR, respectively) knockout mice develop either stronger or reduced emotional disruption during heroin abstinence, establishing DOR and KOR activities as protective and vulnerability factors, respectively, that regulate the severity of abstinence. Further, we found that chronic treatment with the antidepressant drug fluoxetine prevents emergence of low sociability, with no impact on the working memory deficit, implicating serotonergic mechanisms predominantly in emotional aspects of abstinence symptoms. Finally, targeting the main serotonergic brain structure, we show that gene knockout of mu opioid receptors (MORs) in the dorsal raphe nucleus (DRN) before heroin exposure abolishes the development of social withdrawal. This is the first result demonstrating that intermittent chronic MOR activation at the level of DRN represents an essential mechanism contributing to low sociability during protracted heroin abstinence. Altogether, our findings reveal crucial and distinct roles for all three opioid receptors in the development of emotional alterations that follow a history of heroin exposure and open the way towards understanding opioid system-mediated serotonin homeostasis in heroin abuse.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24874714      PMCID: PMC4207349          DOI: 10.1038/npp.2014.126

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  57 in total

1.  Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study.

Authors:  Silvia Mandillo; Valter Tucci; Sabine M Hölter; Hamid Meziane; Mumna Al Banchaabouchi; Magdalena Kallnik; Heena V Lad; Patrick M Nolan; Abdel-Mouttalib Ouagazzal; Emma L Coghill; Karin Gale; Elisabetta Golini; Sylvie Jacquot; Wojtek Krezel; Andy Parker; Fabrice Riet; Ilka Schneider; Daniela Marazziti; Johan Auwerx; Steve D M Brown; Pierre Chambon; Nadia Rosenthal; Glauco Tocchini-Valentini; Wolfgang Wurst
Journal:  Physiol Genomics       Date:  2008-05-27       Impact factor: 3.107

2.  Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal.

Authors:  G C Harris; G Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2001-01       Impact factor: 7.853

3.  Persistence of "relapse-tendencies" of rats previously made physically dependent on morphine.

Authors:  A Wikler; F T Pescor
Journal:  Psychopharmacologia       Date:  1970

4.  GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system.

Authors:  Rui Tao; Sidney B Auerbach
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

5.  Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment.

Authors:  Stephen P Hack; Elena E Bagley; Billy C H Chieng; MacDonald J Christie
Journal:  J Neurosci       Date:  2005-03-23       Impact factor: 6.167

6.  Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine.

Authors:  Celia Goeldner; Pierre-Eric Lutz; Emmanuel Darcq; Thomas Halter; Daniel Clesse; Abdel-Mouttalib Ouagazzal; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

7.  Gender and comorbidity among individuals with opioid use disorders in the NESARC study.

Authors:  Christine E Grella; Mitchell P Karno; Umme S Warda; Noosha Niv; Alison A Moore
Journal:  Addict Behav       Date:  2009-01-30       Impact factor: 3.913

8.  Glucose injections into the medial septum reverse the effects of intraseptal morphine infusions on hippocampal acetylcholine output and memory.

Authors:  M E Ragozzino; P E Gold
Journal:  Neuroscience       Date:  1995-10       Impact factor: 3.590

9.  Kappa opioid receptor-mediated dysregulation of gamma-aminobutyric acidergic transmission in the central amygdala in cocaine addiction.

Authors:  Marsida Kallupi; Sunmee Wee; Scott Edwards; Timothy W Whitfield; Christopher S Oleata; George Luu; Brooke E Schmeichel; George F Koob; Marisa Roberto
Journal:  Biol Psychiatry       Date:  2013-06-14       Impact factor: 13.382

10.  Morphine withdrawal decreases responding reinforced by sucrose self-administration in progressive ratio.

Authors:  Dengke Zhang; Xuhui Zhou; Xuyi Wang; Xiaojun Xiang; Hongxian Chen; Wei Hao
Journal:  Addict Biol       Date:  2007-06       Impact factor: 4.280

View more
  24 in total

1.  Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.

Authors:  Mauricio Romero-Gonzalez; Abtin Shahanaghi; Gregory J DiGirolamo; Gerardo Gonzalez
Journal:  Am J Addict       Date:  2017-11-16

Review 2.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

3.  Roles of the µ-opioid receptor and its related signaling pathways in the pathogenesis of premenstrual syndrome liver-qi stagnation.

Authors:  Chunhong Song; Ling Xue
Journal:  Exp Ther Med       Date:  2017-04-21       Impact factor: 2.447

4.  Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.

Authors:  Lei Zhou; Edward L Stahl; Kimberly M Lovell; Kevin J Frankowski; Thomas E Prisinzano; Jeffrey Aubé; Laura M Bohn
Journal:  Neuropharmacology       Date:  2015-07-06       Impact factor: 5.250

5.  Dissociation of heroin-induced emotional dysfunction from psychomotor activation and physical dependence among inbred mouse strains.

Authors:  G Ayranci; K Befort; L Lalanne; B L Kieffer; P-E Lutz
Journal:  Psychopharmacology (Berl)       Date:  2014-12-09       Impact factor: 4.530

Review 6.  The Opioid-Addicted Tetrapartite Synapse.

Authors:  Anna Kruyer; Vivian C Chioma; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2019-06-13       Impact factor: 13.382

7.  Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol.

Authors:  Jérôme A J Becker; Brigitte L Kieffer; Julie Le Merrer
Journal:  Addict Biol       Date:  2016-04-28       Impact factor: 4.280

8.  Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.

Authors:  Reza Afshari; Majid Khadem-Rezaiyan; Hoda Khatibi Moghadam; Mahdi Talebi
Journal:  Toxicol Res       Date:  2019-11-21

9.  Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.

Authors:  L Lalanne; G Ayranci; D Filliol; C Gavériaux-Ruff; K Befort; B L Kieffer; P-E Lutz
Journal:  Addict Biol       Date:  2016-03-22       Impact factor: 4.280

Review 10.  The Negative Affect of Protracted Opioid Abstinence: Progress and Perspectives From Rodent Models.

Authors:  Lola Welsch; Julie Bailly; Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2019-08-06       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.